Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 41 of 42, showing 5 Applications out of 210 total, starting on record 201, ending on 205

# Protocol No Study Title Investigator(s) & Site(s)

201.

ECCT/25/04/07   Server migration
    Server Migration   
Principal Investigator(s)
1. Server Migration Server Migration
Site(s) in Kenya
Server Migration
 
View

202.

ECCT/25/05/03   Hibiscus 2 - Site 253
    A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease.   
Principal Investigator(s)
1. Fredrick Chite Asirwa
Site(s) in Kenya
1. Site 253 - International Cancer Institute (Uasin Gishu county)
 
View

203.

ECCT/25/05/05   Hibiscus 2 - Site 252
    A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease.   
Principal Investigator(s)
1. Videlis Nduba
Site(s) in Kenya
1. KEMRI CRDR Siaya Clinical Research Annex (Siaya county)
 
View

204.

ECCT/25/05/07   Floral roll over study
    An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study.   
Principal Investigator(s)
1. Prof Jessie Githanga
Site(s) in Kenya
1. Gertrudes Childrens Hospital (Nairobi City county)
2. KEMRI Kondele Children\'s Hospital (Kisumu county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
5. KEMRI WALTER REED KERICHO (Kericho county)
6. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
7. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county)
 
View

205.

ECCT/25/05/12   SAFIRE
    A multicentre open-label, non-inferiority adaptive platform randomised controlled trial to evaluate the efficacy, safety, and tolerability of antimalarials for the treatment of uncomplicated malaria in the first trimester of pregnancy   
Principal Investigator(s)
1. Hellen Barsosio
Site(s) in Kenya
The Kenya Medical Research Institute (KEMRI), Centre for Global Health Research (CGHR)
 
View